Bluprynt | $4,250,000 | (Feb 27, 2026)
UpGuard | $75,000,000 | (Feb 27, 2026)
Revel(US) | $150,000,000 | (Feb 27, 2026)
Certified by Founder
Lodge
Oxford Cancer Analytics
start up
United Kingdom
- Oxford, England
- 10/01/2025
- Series A
- $11,000,000
Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.
- Industry Biotechnology
- Website https://www.oxcan.org/
- LinkedIn https://www.linkedin.com/company/oxford-cancer-analytics/
Alpa | $3,500,000 | (Feb 27, 2026)
ElastixAI | $18,000,000 | (Feb 27, 2026)
Callosum | $10,250,000 | (Feb 27, 2026)
JetScale AI | $5,400,000 | (Feb 27, 2026)
Dots | $8,900,000 | (Feb 27, 2026)
VITURE | $100,000,000 | (Feb 27, 2026)
Ark Climate | $2,478,315 | (Feb 27, 2026)
Jest | $7,000,000 | (Feb 27, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)